Literature DB >> 9118301

A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.

H G Klingemann1, E Wong, G Maki.   

Abstract

Myeloablative chemo-/radiotherapy supported by transplantation of autologous bone marrow or blood progenitor cells for acute leukemia, lymphoma, or myeloma continues to be associated with a high relapse rate because of the infusion of malignant stem cells and the lack of an in vivo graft-vs.-leukemia (GVL) effect. Although various methods of purging are established for marrow, purging procedures for blood progenitor cell preparations have not been widely used primarily because of the technical challenges to process a higher number of cells. As a broadly applicable method for immunological purging, we tested whether highly cytotoxic cells from a natural killer (NK) cell line characterized previously (NK-92) could be used for immunological purging of blood preparations. The NK-92 cell line, which was established from a patient with non-Hodgkin's lymphoma, can lyse in vitro a broad range of leukemia, lymphoma, and myeloma cell lines even at very low effector:target (E:T) ratios; this lysis is superior to cytotoxicity obtained from normal peripheral blood mononuclear cells (PBMCs) stimulated for 4 days with interleukin (IL)-2. In an attempt to quantitate the purging achievable with NK-92 cells, normal PBMCs were spiked with 10% K562 cells that had been transfected with the neo(r) marker gene (K562-neo(r). Various numbers of NK-92 cells were then added to the cell mixtures, which were incubated for 4 or 48 hours at 37 degrees C with or without IL-2 (500 U/mL). In order to prevent their proliferation, NK-92 cells were irradiated with 1000 cGy (cesium source). This radiation dose was determined to suppress proliferation of NK-92 cells, but at the same time maintain full cytotoxic activity. After co-culture, the cells were plated in methylcellulose containing 0.8 mg/mL G418. The number of surviving K562-neo(r) colonies was counted under the microscope 7 days later and the results were considered a quantitative readout for the purging efficacy of NK-92 cells. No neomycin-resistant K562 colonies could be detected up to a ratio of NK-92:K562-neo(r) cells of 5:1 (effective NK-92:PBMC ratio of 0.5:1). The presence or absence of IL-2 during the culture period did not affect the results. At this ratio of NK-92:PBMC, the growth of normal clonogenic hematopoietic progenitor cells was not compromised as determined by a standard methylcellulose assay. Considering that K562 is a rapidly proliferating cell line and that the input number of K562 cells (10%) tested here was high, the data suggest that the cytotoxic NK-92 clone (after irradiation to prevent proliferation) could be used effectively for immunological ex vivo purging without compromising hematopoietic cell function.

Entities:  

Mesh:

Year:  1996        PMID: 9118301

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  34 in total

1.  Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

Authors:  Brenna E Swift; Brent A Williams; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Sowmya Viswanathan; Joaquin Martinez-Lopez; Armand Keating
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.

Authors:  Heike E Daldrup-Link; Reinhardt Meier; Martina Rudelius; Guido Piontek; Morand Piert; Stephan Metz; Marcus Settles; Christoph Uherek; Winfried Wels; Jürgen Schlegel; Ernst J Rummeny
Journal:  Eur Radiol       Date:  2004-12-23       Impact factor: 5.315

Review 3.  [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].

Authors:  G V Kochneva; G F Sivolobova; A V Tkacheva; A A Gorchakov; S V Kulemzin
Journal:  Mol Biol (Mosk)       Date:  2020 Jan-Feb

Review 4.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

5.  Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.

Authors:  Elizabeth L Siegler; Yu Jeong Kim; Xianhui Chen; Natnaree Siriwon; John Mac; Jennifer A Rohrs; Paul D Bryson; Pin Wang
Journal:  Mol Ther       Date:  2017-08-19       Impact factor: 11.454

Review 6.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

7.  Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line.

Authors:  G S D Reid; S Bharya; H-G Klingemann; K R Schultz
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Authors:  Laurent Boissel; Monica Betancur; Winfried S Wels; Hande Tuncer; Hans Klingemann
Journal:  Leuk Res       Date:  2009-01-14       Impact factor: 3.156

9.  A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers.

Authors:  Moein Dehbashi; Zohreh Hojati; Majid Motovali-Bashi; Mohamad Reza Ganjalikhany; William C Cho; Akihiro Shimosaka; Parnian Navabi; Mazdak Ganjalikhani-Hakemi
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 10.  CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.

Authors:  Faroogh Marofi; Alaa S Al-Awad; Heshu Sulaiman Rahman; Alexander Markov; Walid Kamal Abdelbasset; Yulianna Ivanovna Enina; Mahnaz Mahmoodi; Ali Hassanzadeh; Mahboubeh Yazdanifar; Max Stanley Chartrand; Mostafa Jarahian
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.